Next Article in Journal
Pediatric Echocardiographic Nomograms: Twenty Years of Advances—Do We Now Have a Complete and Reliable Tool, or Are Gaps Still Present? An Up-to-Date Review
Previous Article in Journal
The Effects of Active Methamphetamine Use Disorder and Regular Sports Activities on Brain Volume in Adolescents
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Huriez Syndrome and SCC Risk: A Narrative Review Highlighting Surgical Challenges and Oncologic Considerations

1
Hand and Microsurgery Unit, Jewish Hospital, 00148 Rome, Italy
2
Plastic Surgery Unit, Department of Surgery, Sapienza University of Rome, 00185 Rome, Italy
3
Orthopaedic Surgery Unit, Department of Surgery, Sapienza University of Rome, 00185 Rome, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(15), 5214; https://doi.org/10.3390/jcm14155214
Submission received: 21 June 2025 / Revised: 16 July 2025 / Accepted: 17 July 2025 / Published: 23 July 2025

Abstract

Background: Huriez syndrome is a rare hereditary skin disorder marked by early-onset sclerodactyly, hyperkeratosis of the palms and soles, and nail dysplasia. A key concern is the early and aggressive development of cutaneous squamous cell carcinoma (SCC), typically affecting the dorsal aspects of the hands. Methods: This narrative review summarizes clinical features, genetic aspects, and oncologic implications of Huriez syndrome. A systematic search was conducted in PubMed and Scopus, including English-language articles published up to May 2025. Relevant case reports and small case series were analyzed. Results: Seven patients (58.3%) underwent multiple surgeries due to recurrent or bilateral disease. Six patients (50%) required amputations, including finger, hand, and arm amputations, with no foot amputations reported. Reconstruction after oncological resection was performed in six patients (50%) using skin grafts (3), pedicled flaps (2), or free flaps (1). Amputation was mainly for advanced disease, with radial forearm flaps used for reconstruction. All flaps remained disease-free. Five cases (41.6%) had a history of local recurrence. Conclusions: The early diagnosis of Huriez syndrome is crucial to enable the surveillance and timely treatment of SCC. A multidisciplinary team including dermatologists, oncologists, plastic surgeons, and geneticists is recommended. Further research is needed to clarify genetic mechanisms and develop early detection strategies to improve outcomes.

1. Introduction

Squamous cell carcinoma (SCC) is the most prevalent form of primary malignant tumor found in the hand [1]. SCC arises from the malignant transformation of keratinocytes and shows varying levels of aggressiveness, influenced by factors like tumor differentiation, anatomical site, immune system status, and delay in diagnosis. It is significantly more common in the hand than basal cell carcinoma (BCC), with a BCC to SCC ratio of 1:14 [2]. Unlike BCC, SCC has a higher potential for local invasion, bone involvement, and lymphatic metastasis, necessitating early detection and intervention. SCC progresses from precursor lesions like actinic keratosis to carcinoma in situ (Bowen’s disease) and eventually to invasive SCC [3].
The development of SCC is primarily driven by chronic ultraviolet (UV) radiation exposure, especially in sun-exposed areas like the dorsal hands. Other contributing factors include carcinogenic agents such as arsenic, polycyclic hydrocarbons, and Human Papilloma Virus (HPV) infections. Additionally, individuals with genetic conditions like xeroderma pigmentosum and Huriez syndrome and those with chronically inflamed or damaged skin, are at higher risk for SCC development.
Huriez syndrome, also known as sclerotylosis, is a rare autosomal dominant genodermatosis characterized by congenital scleroatrophy of the distal extremities, palmoplantar keratoderma, and nail hypoplasia [4,5]. First described in 1963 in two French families, it has since been reported in fewer than 50 cases worldwide, making it one of the rarest cancer-prone genodermatoses [6,7,8]. A hallmark of this condition is the development of aggressive cutaneous squamous cell carcinoma (SCC), particularly on the dorsal aspect of the hands, often at an early age (Figure 1). Unlike SCCs associated with chronic sun exposure or immunosuppression, those arising in Huriez syndrome may follow a more rapid clinical course and are more prone to local recurrence or regional lymph node metastasis [9,10], necessitating wide local excisions or even amputations, similar to what is needed for other soft tissue tumors of the hand [11].
Reports suggest that up to 15–20% of affected individuals develop SCC, usually before the age of 45, which underscores the malignant potential of this syndrome [12]. Clinically, the syndrome often begins at birth or early infancy with signs of scleroatrophy, tightly adherent skin on the hands and feet, and progressive keratoderma. Nail hypoplasia may develop during childhood, often leading to significant nail plate dystrophy or anonychia. Some patients may also exhibit features of poikiloderma, hypopigmentation, or sweat gland dysfunction [13,14]. Although its exact genetic basis remains unclear, recent studies have identified a possible link to pathogenic variants in the SMARCAD1 gene, which encodes a chromatin remodeling helicase with a role in maintaining skin barrier integrity [15]. These findings have expanded the spectrum of genodermatoses associated with chromatin remodeling defects and may explain the high susceptibility to early oncogenesis observed in these patients. Due to its rarity, there are currently no standardized surveillance protocols or management guidelines specific to Huriez syndrome. While small, low-risk lesions of hand SCC are commonly treated with shave excision, curettage, cryotherapy, or Mohs micrographic surgery, SCC in Huriez patients is characterized by earlier onset, more aggressive behavior, and a higher incidence of metastasis, making it unsuitable for standard low-risk management.
Nevertheless, delay or avoidance of biopsy is frequently observed due to the atypical presentation and chronicity of skin changes, which, in turn, contributes to the risk of late-stage SCC diagnosis. In the absence of guidelines, the early identification of clinical signs, regular dermatologic follow-up, and a low threshold for biopsy of suspicious lesions are crucial in preventing advanced-stage disease [16,17]. Despite the recognition of the syndrome’s increased risk for aggressive SCC, there are only a few reports in the literature regarding its surgical management and treatment protocols. This lack of comprehensive data underscores the absence of standardized guidelines for the management of Huriez syndrome, especially in terms of early diagnosis, treatment strategies, and post-operative care. The aim of this narrative review is to consolidate the available clinical evidence on Huriez syndrome, with a particular focus on the management of SCC in this rare and complex condition. In addition to synthesizing the existing literature, we integrate our own clinical experience in managing Huriez syndrome, emphasizing key treatment pearls that should be considered when treating patients with this disease. By combining evidence from the literature with our practical insights, we highlight critical factors for successful management, offering valuable guidance for clinicians dealing with the challenges posed by Huriez syndrome and its associated complications.

2. Materials and Methods

2.1. Search Strategy and Study Selection

For this narrative review, a comprehensive search was conducted across electronic databases, including MEDLINE, Pubmed, Pubmed Central (PMC), and the Cochrane Library, targeting clinical studies related to Huriez syndrome. The search strategy utilized Medical Subject Headings (MeSHs) and specific keywords: “Huriez syndrome [MeSH]” and sclerotylosis [MeSH]”. This narrative review was conducted with attention to methodological quality, following the guidance outlined in the Scale for the Assessment of Narrative Review Articles (SANRA) and referring to relevant aspects of the PRISMA-ScR checklist, though not conducted as a formal scoping review as defined by PRISMA-ScR [18].
Only articles published in English were considered. Eligible studies included case reports, small case series, and narrative or pictorial reviews with detailed clinical descriptions and histopathological confirmation. Articles lacking clinical data, not directly related to Huriez syndrome, or without confirmed SCC were excluded. Titles and abstracts were screened first, followed by full-text analysis of relevant records.

2.2. Data Extraction and Analysis

Extracted data included patient demographics, clinical phenotype, age at diagnosis, family history, the presence and characteristics of SCC, localization, histopathological findings, treatment approaches, and follow-up. Special focus was given to features of malignant transformation, recurrence patterns, and reconstructive strategies.
Data extraction was conducted independently by two authors (AP and DR). Disa-greements on study eligibility were resolved through consensus discussions with the other authors. Reference lists from the retrieved articles were examined to ensure that a comprehensive literature search was performed.
Given the rarity of Huriez syndrome and variability in published cases, statistical synthesis was not feasible. The results are, therefore, presented as a qualitative descriptive synthesis, aimed at identifying consistent patterns, highlighting diagnostic challenges, and outlining areas for future research.

3. Results

A total of 30 studies were identified in the initial search. After screening titles and abstracts, nine papers on Huriez syndrome-related SCC were included in the final review. The full texts and references were carefully reviewed to identify additional relevant studies (Figure 2).

3.1. Demographic and Clinical Characteristics

A total of 9 studies published between 1995 and 2024 were included, reporting on 12 patients diagnosed with Huriez syndrome complicated by cutaneous SCC [8,19,20,21,22,23,24,25,26]. Of these, seven were male (58.3%) and five were female (41.7%). The average age at SCC diagnosis was 46.7 years (±11.6), with a median of 43 years (range: 22–62) (Table 1).

3.2. Tumor Localization and Laterality

All 12 patients (100%) developed SCC in the hands, with 3 cases (25%) also involving the feet. Among those with hand involvement, three patients (25%) had bilateral disease, whereas nine (75%) were unilateral. The palmar and volar surfaces were frequently involved, with recurrent tumors often requiring more extensive resections.

3.3. Surgical Management

Seven patients (58.3%) underwent multiple surgeries due to recurrent, bilateral disease or hand/foot involvement. Six (50%) patients underwent amputations. The amputation of fingers, hand, and arm is described in four papers. Five patients (41.6%) had multiple and bilateral finger amputations. No foot amputations were described in Huriez patients. Six patients (50%), after oncological resection, underwent reconstruction with skin grafts (3), pedicled flaps (2), or free flaps (1).
  • Amputation. Cases requiring finger amputation had locally advanced disease or recurrence. The index was the most affected finger (50%) (Figure 3). The palmo-volar skin was the area affected in all cases. Two patients had wrist and arm amputation. The wrist amputation was decided in a patient who had had six local recurrences. The patient with arm amputation died from lung metastatis.
  • Skin grafts. Five cases were treated with excision and skin grafts. In three cases, revision surgery was necessary for recurrences or inadequate margins.
  • Skin flaps, pedicled and free. Two patients were treated with radial forearm flap for third ray reconstruction, after second ray amputation [24,26]. The flap was harvested from the forearm, where the skin was unaffected by scleroatrophy. In both cases, the skin of the flaps at the recipient site remained free of the disease. One patient had SCC in the right foot and was treated with a free radial forearm flap harvested from the amputated arm.

3.4. Recurrence and Histological Grading

Data for local recurrence were present in five of the nine papers. Five cases (41.6%) experienced local recurrences, including a case with six documented relapses prior to wrist amputation. Histologically, 67% of tumors were classified as Grade 1 (well-differentiated), 13% were classified as Grade 2 (moderately differentiated), and 20% were reported as carcinoma in situ. Recurrences were often linked to incomplete surgical margins and delays in initial biopsy.

3.5. Metastasis and Outcomes

Metastatic spread occurred in four patients (33.3%), primarily involving lymph nodes and lungs, who subsequently died from metastatic disease. The patient described by Guerriero was 60 years old, with hand and foot localization and sustained arm amputation. Three patients described before the 2000s by Kavanach, Hamm and Delaporte died from metastatic disease. The patient described by Delaporte was 35 years old and sustained multiple recurrences in both hands. The younger patient, aged 22 years old, as reported by the sister of the patient, was the only female patient who died from disease, and her medical history was briefly described in the paper of Kavanach.

4. Discussion

4.1. Clinical and Oncologic Implications of SCC in Huriez Syndrome

Huriez syndrome is recognized as a cancer-prone genodermatosis due to its strong association with cutaneous SCC, particularly in the acral regions. Unfortunately, the development of SCC remains the most important prognostic element for these patients. The review of the available literature confirms that SCC in these patients tends to occur at a relatively young age, with a median of 43 years. All reported cases involved the hands, and 25% also showed foot involvement, highlighting the typical acral predilection of tumor development in this syndrome. The aggressive nature of SCC in Huriez syndrome, with early onset and potential for multifocality, reinforces the need for heightened clinical suspicion and prompt histological confirmation of suspicious lesions. The chronic scleroatrophy and keratoderma can obscure early signs of malignancy, contributing to diagnostic delays.

4.2. Recurrence and Metastatic Risk

Local recurrence was reported in 41.6% of cases, often associated with incomplete surgical margins and delayed biopsies. One patient experienced six local recurrences prior to undergoing wrist amputation, highlighting the critical importance of adequate initial resection, similar to what is needed for other soft tissue tumors of the hand [27,28,29,30,31,32,33]. Histologically, the majority of tumors were well-differentiated (67%), but moderately differentiated and in situ lesions were also observed. While histologic grading can provide insights into tumor behavior, it does not fully predict recurrence or metastatic potential in these patients. Notably, metastasis to regional lymph nodes or lungs occurred in 33.3% of cases, with a total of four patients succumbing to the disease. This included a 22-year-old woman, illustrating that even young patients are not spared from aggressive tumor progression.

4.3. Surgical Management and Reconstructive Challenges

The management of cutaneous SCC in Huriez syndrome presents unique challenges and often requires multiple surgical procedures. In the cohort analyzed, 58.3% of patients underwent more than one operation due to recurrences or multifocal disease.
Delayed diagnoses not only complicate treatment but also compromise hand dexterity and prehension following demolitive surgery, emphasizing the importance of early recognition and management. The treatment of SCC in Huriez syndrome generally involves oncological surgical excision, but several factors complicate management. First, rapid tumor growth is common, with early invasion into tendons, neurovascular bundles, and bone tissues, making complete resection particularly challenging. Second, the presence of scleroatrophy in the peritumoral skin makes it difficult to achieve clear surgical margins, as the affected skin often appears suspicious, increasing the risk of incomplete excision and local recurrence. In planning resection, margins should be wider than 1 cm in the presence of suspicious areas [24], because incomplete excision is a major cause of local recurrences and amputation.
Third, local flaps, which are commonly used in hand reconstruction, are often impractical due to the high likelihood of additional precancerous or cancerous lesions in surrounding tissue, further complicating the reconstruction process. In cases of significant tissue loss involving the exposure of bone, tendons, and neurovascular pedicles, the radial forearm flap proved to be the optimal choice, as it is harvested from an unaffected area. As highlighted in our previous study [26], flaps play a crucial role in disease management, as the skin grafts remain unaffected by the disease, while the surrounding skin benefits from the flap placement, leading to a regression of scleroatrophy. Consistent with the recommendations of other authors [22,24], we believe that preventive excision with grafts or flaps could be considered for these patients, provided it is supported by a multidisciplinary team evaluation.
These factors necessitate a comprehensive, multidisciplinary approach to treatment. We believe that careful planning and management are essential for optimal outcomes in these patients. A thorough evaluation by a multidisciplinary team, including dermatologists, plastic surgeons, and oncologists, is crucial to address the complexities of this condition.

4.4. Surveillance and Multidisciplinary Strategy

Given the rarity and severity of Huriez syndrome, there are no standardized surveillance protocols. The small number of published studies and limited cohort sizes significantly restrict the ability to generalize conclusions or formulate definitive treatment guidelines. Furthermore, most studies lack long-term follow-up data, leaving long-term outcomes and potential complications poorly understood. These limitations underscore the need for further research, including larger studies with extended follow-up periods, to develop more comprehensive management strategies and improve clinical outcomes for patients with Huriez syndrome. However, the available data support the need for proactive monitoring and early intervention. Regular dermatologic evaluations and a low threshold for performing biopsies are recommended, particularly when lesions exhibit changes in texture, color, or growth. In many cases, delays in biopsy were associated with advanced disease at diagnosis.
We want to highlight that biopsy is the first step of the treatment to confirm diagnosis and grading. According to the INCa-HAS recommendations of 2009, titled “Diagnostic and therapeutic management of cutaneous squamous cell carcinoma”, the excision of the infiltrating cSCC should have margins of one centimeter [34]. A multidisciplinary approach involving dermatologists, oncologists, plastic surgeons, and geneticists is essential for optimal care. Genetic counseling should also be considered, given the hereditary nature of the syndrome and emerging evidence linking it to SMARCAD1 mutations.

4.5. Future Directions

Given the rarity of Huriez syndrome, collaborative efforts are essential to expand clinical knowledge and improve management. Key areas for future research include multicenter registries to better define incidence, clinical variability, and prognosis as well as shared clinical guidelines to standardize surveillance and early intervention for suspicious lesions.
Using advanced imaging techniques, possibly supported by artificial intelligence, to enhance early SCC detection may increase patient survival or avoid ample resections in the future. Currently, there is no definitive evidence to suggest that performing a lymph-node biopsy improves prognosis in these patients, and future research is needed to clarify if patients will benefit from this practice [35,36,37,38,39,40,41].

5. Conclusions

Huriez syndrome represents an exceptionally rare genodermatosis with a high risk of developing early-onset and aggressive cutaneous squamous cell carcinoma, particularly on the hands. Despite the limited number of reported cases, a consistent pattern of clinical features and surgical challenges emerges, including frequent local recurrences, high rates of amputation, and a non-negligible risk of metastasis. Early biopsy is paramount for accurate diagnosis and staging, followed by the early and ample resection of the tumor to ensure adequate margins and reduce the risk of recurrence. Reconstruction with distant flaps, such as radial forearm flaps or free flaps, should be considered for coverage, as these techniques offer disease-free tissue for hand reconstruction, minimizing the risk of recurrence and providing functional outcomes. In our clinical experience, this approach ensures that the hand remains covered with healthy, non-sclerotic tissue, optimizing both oncologic and functional results.

Author Contributions

Conceptualization, A.P. and L.P.; methodology, F.L.T. and D.R.; validation, F.L.T., A.P. and D.R.; formal analysis, F.L.T., L.P. and F.S.L.; investigation, F.L.T., L.P., C.Z. and A.P.; resources, A.P. and L.P.; data curation, A.P. and L.P.; writing—original draft preparation, A.P., L.P. and F.S.L.; writing—review and editing, L.P. and A.P.; visualization, A.P.; supervision, F.L.T. and A.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Ilyas, E.N.; Leinberry, C.F.; Ilyas, A.M. Skin cancers of the hand and upper extremity. J. Hand Surg. 2012, 37, 171–178. [Google Scholar] [CrossRef]
  2. Subramaniam, P.; Olsen, C.M.; Thompson, B.S.; Whiteman, D.C.; Neale, R.E. Skin Sun and Health Study Investigators. Ana-tomical Distributions of Basal Cell Carcinoma and Squamous Cell Carcinoma in a Population-Based Study in Queens-land, Australia. JAMA Dermatol. 2017, 153, 175–182. [Google Scholar] [CrossRef]
  3. Preston, D.S.; Stern, R.S. Nonmelanoma cancers of the skin. N. Engl. J. Med. 1992, 327, 1649–1662. [Google Scholar] [CrossRef]
  4. Huriez, C.; Agache, P.; Bombart, M. Scléroatrophie congénitale familiale avec kératodermie palmo-plantaire et hypoplasie unguéale. Bull Soc. Fr. Dermatol. Syphiligr. 1963, 70, 24–28. [Google Scholar]
  5. Çelik, N.S.; Yaşar, Ş.; Aytekin, S.; Güneş, P. A Rare Syndrome Resembling Scleroderma: Huriez Syndrome. Skin Appendage Disord. 2018, 4, 82–85. [Google Scholar] [CrossRef]
  6. Man, X.Y.; Li, W.; Chen, J.Q.; Zhou, J.; Liao, Y.J.; Li, C.M.; Cai, S.Q.; Zheng, M. Huriez syndrome with squamous cell carcinoma. Eur. J. Dermatol. 2011, 21, 294–295. [Google Scholar] [CrossRef]
  7. Grigatti, M.; Pescarini, E.; Salmaso, R.; Gardener, C.; Brambullo, T.; Vindigni, V. Huriez syndrome associated with basal cell carcinoma. A case report. Ann. Ital. Chir. 2020, 9, S2239253X20032454. [Google Scholar]
  8. Hamm, H.; Traupe, H.; Bröcker, E.B.; Schubert, H.; Kolde, G. The scleroatrophic syndrome of Huriez: A cancer-prone genodermatosis. Br. J. Dermatol. 1996, 134, 512–518. [Google Scholar] [CrossRef]
  9. Sekar, S.C.; Srinivas, C.R. Huriez syndrome. Indian J. Dermatol. Venereol. Leprol. 2008, 74, 409–410. [Google Scholar] [CrossRef]
  10. Sayed, L.; Deodhar, A.K.; Agarwal, R. Squamous cell carcinoma of the upper limb requiring amputation: A review. JPRAS Open 2019, 20, 43–58. [Google Scholar] [CrossRef]
  11. Pagnotta, A.; Formica, V.M.; Taccogna, S.; Summa, G.; Zoccali, C. High-Grade Chondrosarcoma of the Proximal Phalanx: An Unusual Case of a Rare Entity. High-Grade chondrosarkom proximálního článku: Neobvyklý případ vzácné entity. Acta Chir. Orthop. Traumatol. Cech. 2023, 90, 63–66. [Google Scholar] [CrossRef]
  12. Patrignani, A.; Pagnotta, A.; Amendola, C.; Bruno, E.; Torto, F.L.; Ribuffo, D. Hand reconstruction in Huriez syndrome: The “therapeutic” role of distant flaps. Hand Surg. Rehabil. 2024, 43, 101781. [Google Scholar] [CrossRef]
  13. Patrizi, A.; Di Lernia, V.; Patrone, P. Palmoplantar keratoderma with sclerodactyly (Huriez syndrome). J. Am. Acad. Dermatol. 1992, 26 Pt 2, 855–857. [Google Scholar] [CrossRef] [PubMed]
  14. Goldminz, D.; Bennett, R.G. Mohs surgery in the nail unit. J. Dermatol. Surg. Oncol. 1992, 18, 721–726. [Google Scholar] [CrossRef]
  15. Loh, A.Y.T.; Špoljar, S.; Neo, G.Y.W.; Escande-Beillard, N.; Leushacke, M.; Luijten, M.N.H.; Venkatesh, B.; Bonnard, C.; van Steensel, M.A.M.; Hamm, H.; et al. Huriez syndrome: Additional pathogenic variants supporting allelism to SMAR-CAD syndrome. Am. J. Med. Genet. Part A 2022, 188, 1752–1760. [Google Scholar] [CrossRef]
  16. Askari, M.; Kakar, S.; Moran, S.L. Squamous cell carcinoma of the hand: A 20-year review. J. Hand Surg. 2013, 38, 2124–2133. [Google Scholar] [CrossRef]
  17. De Angelis, B.; Balzani, A.; Pagnotta, A.; Tati, E.; Orlandi, F.; D’Autilio, M.F.L.M.; Cervelli, V.; Gentile, P. Malignant Skin Cancer Excision in Combined Therapy with Electro-Chemotherapy and Dermal Substitute. Curr. Oncol. 2021, 28, 1718–1727. [Google Scholar] [CrossRef]
  18. Tricco, A.C.; Lillie, E.; Zarin, W.; O’Brien, K.K.; Colquhoun, H.; Levac, D.; Moher, D.; Peters, M.D.J.; Horsley, T.; Weeks, L.; et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann. Intern. Med. 2018, 169, 467–473. [Google Scholar] [CrossRef]
  19. Delaporte, E.; N’guyen-Mailfer, C.; Janin, A.; Savary, J.B.; Vasseur, F.; Feingold, N.; Piette, F.; Bergoend, H. Keratoderma with scleroatrophy of the extremities or sclerotylosis (Huriez syndrome): A reappraisal. Br. J. Dermatol. 1995, 133, 409–416. [Google Scholar] [CrossRef]
  20. Kavanagh, G.M.; Jardine, P.E.; Peachey, R.D.; Murray, J.C.; De Berker, D. The scleroatrophic syndrome of Huriez. Br. J. Dermatol. 1997, 137, 114–118. [Google Scholar] [CrossRef]
  21. Watanabe, E.; Takai, T.; Ichihashi, M.; Ueda, M. A nonfamilial Japanese case of Huriez syndrome: p53 expression in squamous cell carcinoma. Dermatology 2003, 207, 82–84. [Google Scholar] [CrossRef] [PubMed]
  22. Riggio, E.; Spano, A.; Bonomi, S.; Nava, M. Huriez syndrome: Association with squamous cell carcinoma and a surgical approach. Plast. Reconstr. Surg. 2005, 116, 689–691. [Google Scholar] [CrossRef] [PubMed]
  23. Guerriero, C.; Albanesi, C.; Girolomoni, G.; De Simone, C.; Capizzi, R.; Amerio, P.; Tulli, A. Huriez syndrome: Case report with a detailed analysis of skin dendritic cells. Br. J. Dermatol. 2000, 143, 1091–1096. [Google Scholar] [CrossRef] [PubMed]
  24. Dumont, L.A.; Gahagnon, T.; Martinot-Duquennoy, V.; Mortier, L.; Guerreschi, P. Cas clinique: Carcinome épidermoïde, lambeau antébrachial radial et syndrome d’Huriez. Mise au point sur une pathologie rare [Case report: Squamous cell carcinoma, radial forearm flap and Huriez syndrome. Focus on a rare pathology]. Ann. Chir. Plast. Esthet. 2013, 58, 175–179. [Google Scholar] [CrossRef]
  25. Halbony, H.; Bekerecioglu, M.; Kocarslan, S. Huriez a Squamous Cell Carcinoma Prone Syndrome: A Case Report. Med. Case Rep. 2022, 8, 229. [Google Scholar]
  26. Patrignani, A.; Ribuffo, D.; Greco, A.; Lo Torto, F.; Pagnotta, A. Squamous cell carcinoma in rare case of Huriez Syndrome: The role of distant flaps. JPRAS Open 2024, 43, 180–186. [Google Scholar] [CrossRef]
  27. Pagnotta, A.; Formica, V.M.; Ascione, A.; Covello, R.; Zoccali, C. Massive bone allograft engineered with autologous vessels: A new perspective for the future. Hand Surg. Rehabil. 2022, 41, 648–653. [Google Scholar] [CrossRef]
  28. Troisi, L.; Zanchetta, F.; Berner, J.E.; Mosillo, G.; Pajardi, G.E. Reconstruction of Digital Defects with the Free Proximal Ulnar Artery Perforator Flap. Plast. Reconstr. Surg. Glob. Open 2022, 10, e4054. [Google Scholar] [CrossRef]
  29. Vizcay, M.; Pajardi, G.E.; Zanchetta, F.; Stucchi, S.; Baez, A.; Troisi, L. Tailored Skin Flaps for Hand Reconstruction. Plast. Reconstr. Surg. Glob. Open 2022, 10, e4538. [Google Scholar] [CrossRef]
  30. Cornacchini, J.; Oubari, H.; Tereshenko, V.; Bejar-Chapa, M.; Berkane, Y.; Scarabosio, A.; Lellouch, A.G.; Camuzard, O.; Eberlin, K.R.; Lupon, E. Update/Refinement of Targeted Muscle Reinnervation Indication: A Scoping Review of Applications for Non-Amputees. J. Clin. Med. 2024, 13, 6107. [Google Scholar] [CrossRef]
  31. Marcasciano, M.; Mazzocchi, M.; Kaciulyte, J.; Spissu, N.; Casella, D.; Ribuffo, D.; Dessy, L.A. Skin cancers and dermal substitutes: Is it safe? Review of the literature and presentation of a 2-stage surgical protocol for the treatment of non-melanoma skin cancers of the head in fragile patients. Int. Wound J. 2018, 15, 756–768. [Google Scholar] [CrossRef]
  32. Fino, P.; Spagnoli, A.M.; Ruggieri, M.; Marcasciano, M.; Scuderi, N. Bilateral hand squamous-cells carcinoma in patient affected with non-Hodgkin lymphoma. Case report and literature review. G. Chir. 2015, 36, 172–182. [Google Scholar] [CrossRef]
  33. Diluiso, G.; Pozzi, M.; Liso, F.G.; Mendes, V.M.; Hannouille, J.; Losco, L.; Bolletta, A.; Cigna, E.; Schettino, M. Mind the Gap: A Questionnaire on the Distance between Diagnostic Advances and Clinical Practice in Skin Cancer Treatment. Medicina 2024, 60, 155. [Google Scholar] [CrossRef]
  34. French Society of Dermatology. Carcinome épidermoïde cutané (carcinome spinocellulaire): Recommandations de pratique clinique pour la prise en charge diagnostique et théapeutique. Argumentaire-Mai 2009 [Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. Arguments-May 2009]. Ann. Dermatol. Venereol. 2009, 136 (Suppl. S5), S189–S242. [Google Scholar]
  35. Takeda, A.; Akimoto, M.; Nemoto, M.; Kounoike, N.; Uchinuma, E. Preoperative risk factors of lymph node metastasis in cutaneous squamous cell carcinoma. J. Plast. Surg. Hand Surg. 2013, 47, 204–208. [Google Scholar] [CrossRef] [PubMed]
  36. Cuccia, G.; Colonna, M.R.; Papalia, I.; Manasseri, B.; Romeo, M.; d’Alcontres, F.S. The use of sentinel node biopsy and selective lymphadenectomy in squamous cell carcinoma of the upper limb. Usefulness of sentinel node biopsy to avoid useless lymphadenectomies in high-risk upper limb SCC. Ann. Ital. Chir. 2008, 79, 67–71. [Google Scholar] [PubMed]
  37. Terry, P.H.; Toyoda, Y.; Lin, I.C. Skin Cancer of the Hand: Current Management and New Horizons. J. Hand Surg. Am. 2025, 50, 732–740. [Google Scholar] [CrossRef]
  38. Page, F.; Chester, D. Outcomes of 100 Squamous Cell Carcinomas of the Upper Limb: 100 Squamous Cell Carcinomas of the Upper Limb. Ann. Plast. Surg. 2025, 94, 296–301. [Google Scholar] [CrossRef]
  39. Wei, L.Y.; Li, Z.Z.; Xu, Z.Y.; Wang, G.R.; Xiao, Y.; Liu, B.; Bu, L.L. The ending is not the end: Lymph node metastasis in oral squamous cell carcinoma. Int. Immunopharmacol. 2025, 146, 113917. [Google Scholar] [CrossRef]
  40. English, C.; Hammert, W.C. Cutaneous malignancies of the upper extremity. J. Hand Surg. Am. 2012, 37, 367–377. [Google Scholar] [CrossRef]
  41. Crosbie, E.J.; Winter-Roach, B.; Sengupta, P.; Sikand, K.A.; Carrington, B.; Murby, B.; Slade, R.J. The accuracy of the sentinel node procedure after excision biopsy in squamous cell carcinoma of the vulva. Surg. Oncol. 2010, 19, e150–e154. [Google Scholar] [CrossRef]
Figure 1. A patient with Huriez syndrome and a cutaneous SCC of the second finger.
Figure 1. A patient with Huriez syndrome and a cutaneous SCC of the second finger.
Jcm 14 05214 g001
Figure 2. PRISMA flow diagram. (1) Not in English, letter, book section, experimental, animal studies.
Figure 2. PRISMA flow diagram. (1) Not in English, letter, book section, experimental, animal studies.
Jcm 14 05214 g002
Figure 3. The same patient as in Figure 1, following the second finger amputation. The patient healed well with optimal functional recovery.
Figure 3. The same patient as in Figure 1, following the second finger amputation. The patient healed well with optimal functional recovery.
Jcm 14 05214 g003
Table 1. The literature review.
Table 1. The literature review.
AuthorsN° PatientsAgeGenderLocalizationHistologySurgeryRecurrenceFUMetastasis
Patrignani et al. (2024) [26]155MR Hand
L Hand
R Foot
G1
G1
G1
G1
Wrist amputation
2nd ray amputation
Radial forearm flap
Free radial forearm flap
6
1
5 y
3 y
2 y
___
Halbony et al. (2022) [25]141FR Foot
R Hand
In situ
In situ
Ex, skin graft___2y___
Dumont et al. (2013) [24]162ML HandG1Fingers amputation
2nd ray amputation
Skin graft
Radial forearm flap
21 y___
Guerriero et al. (2008) [23]160MR Hand
R Foot
Arm amputation
Ex
___1 yLung
Riggio et al. (2005) [22]146ML Hand
R Hand
G1
G2
G1
G1
Ipothenar ex, skin graft
Palmar ex, skin graft
Ipothenar ex, skin graft
Amputation 4th + 5th ray
1
1
N (G1)
Watanabe et al., 2003 [21]141FL Hand
R Hand
G1
In situ
Thumb amputation
Thumb ex, skin graft
1y______
Kavanagh et al. (1997) [20]222
45
F
F
Hand
Hand
____________M
Hamm et al. (1996) [8]137FR HandG2Thenar M (N + Lung)
Delaporte et al. (1995) [19]335
55
39
M
M
M
Hands
R Hand
L Hand
G1Fingers
Thumb
2nd ray amputation
7 M
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pagnotta, A.; Patanè, L.; Zoccali, C.; Loria, F.S.; Lo Torto, F.; Ribuffo, D. Huriez Syndrome and SCC Risk: A Narrative Review Highlighting Surgical Challenges and Oncologic Considerations. J. Clin. Med. 2025, 14, 5214. https://doi.org/10.3390/jcm14155214

AMA Style

Pagnotta A, Patanè L, Zoccali C, Loria FS, Lo Torto F, Ribuffo D. Huriez Syndrome and SCC Risk: A Narrative Review Highlighting Surgical Challenges and Oncologic Considerations. Journal of Clinical Medicine. 2025; 14(15):5214. https://doi.org/10.3390/jcm14155214

Chicago/Turabian Style

Pagnotta, Alessia, Luca Patanè, Carmine Zoccali, Francesco Saverio Loria, Federico Lo Torto, and Diego Ribuffo. 2025. "Huriez Syndrome and SCC Risk: A Narrative Review Highlighting Surgical Challenges and Oncologic Considerations" Journal of Clinical Medicine 14, no. 15: 5214. https://doi.org/10.3390/jcm14155214

APA Style

Pagnotta, A., Patanè, L., Zoccali, C., Loria, F. S., Lo Torto, F., & Ribuffo, D. (2025). Huriez Syndrome and SCC Risk: A Narrative Review Highlighting Surgical Challenges and Oncologic Considerations. Journal of Clinical Medicine, 14(15), 5214. https://doi.org/10.3390/jcm14155214

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop